Zafirlukast
A leukotriene receptor inhibitor, effective in asthma. It is a selective antagonist of leukotriene D 4 recptor, stimulation of which by circulating leukotrienes is thought to play a role in pathogenesis of asthma. It suppresses both early and late bronchoconstrictor responses to inhaled antigens and irritants.
Primary Characteristics
It is of Synthetic origin.
Molecular Weight: 575.5 · Solubility in Water: insoluble · Non-proprietary name: Zafirlukast.
Pharmacokinetics
Distribution: Zafirlukast has a plasma protein binding is 99 %.
Elimination: plasma half-life is 10 hr, renal excretion is 10 % unchanged.
Advertisement
Indications
Zafirlukast is primarily indicated in conditions like Allergic rhinitis, Prophylaxis of asthma.
Contraindications
Zafirlukast is contraindicated in conditions like Renal impairment, Hepatic impairment, Hypersensitivity.
Dosage
Zafirlukast's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 20 mg | 20 mg | Every 12h | PO | |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Zafirlukast in overdosage may give rise to further complications which include Hyperbilirubinemia, Symptomatic hepatitis.
Zafirlukast produces potentially life-threatening effects which include Neuropathy , Cardiac complication. Careful monitoring is needed with proper medical management.
Zafirlukast is known to cause more or less tolerable side effects which are usually transient. These include Dizziness, Fever, GI disturbance, Headache, Myalgia, Pain , Respiratory tract infections.
Warnings / Precautions
Available Brands
Storage Conditions
Drug Classification
- 1.25.1.1 — Oral/Parenteral antiasthmatics